Nature Communications (Apr 2022)

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

  • Marie-Eve Wedge,
  • Victoria A. Jennings,
  • Mathieu J. F. Crupi,
  • Joanna Poutou,
  • Taylor Jamieson,
  • Adrian Pelin,
  • Giuseppe Pugliese,
  • Christiano Tanese de Souza,
  • Julia Petryk,
  • Brian J. Laight,
  • Meaghan Boileau,
  • Zaid Taha,
  • Nouf Alluqmani,
  • Hayley E. McKay,
  • Larissa Pikor,
  • Sarwat Tahsin Khan,
  • Taha Azad,
  • Reza Rezaei,
  • Bradley Austin,
  • Xiaohong He,
  • David Mansfield,
  • Elaine Rose,
  • Emily E. F. Brown,
  • Natalie Crawford,
  • Almohanad Alkayyal,
  • Abera Surendran,
  • Ragunath Singaravelu,
  • Dominic G. Roy,
  • Gemma Migneco,
  • Benjamin McSweeney,
  • Mary Lynn Cottee,
  • Egon J. Jacobus,
  • Brian A. Keller,
  • Takafumi N. Yamaguchi,
  • Paul C. Boutros,
  • Michele Geoffrion,
  • Katey J. Rayner,
  • Avijit Chatterjee,
  • Rebecca C. Auer,
  • Jean-Simon Diallo,
  • Derrick Gibbings,
  • Benjamin R. tenOever,
  • Alan Melcher,
  • John C. Bell,
  • Carolina S. Ilkow

DOI
https://doi.org/10.1038/s41467-022-29526-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

RNA-based viruses can be engineered to express artificial microRNAs (amiRNAs). Here, the authors identify a candidate amiRNA that confers a replicative advantage to oncolytic viruses, enhancing their anticancer potency, and show that intercellular transfer of extracellular vesicles carrying the amiRNA promotes bystander killing of uninfected cancer cells.